Send to

Choose Destination
J Clin Urol. 2018 May;11(3):192-199. doi: 10.1177/2051415818762683. Epub 2018 Mar 5.

Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method.

Author information

Academic Urology Group, University of Cambridge, Cambridge, UK.
Department of Urology, Addenbrooke's Hospital, Cambridge, UK.
Cambridge Urology Translational Research and Clinical Trials, University of Cambridge, Cambridge, UK.
Medical Physics and Clinical Engineering, Addenbrooke's Hospital, Cambridge, UK.



The aim of this study was to pilot the use of a bespoke device (CAMPROBE, the CAMbridge PROstate Biopsy) to enable routine outpatient free-hand local anaesthetic (LA) transperineal prostate biopsies.

Materials and methods:

The CAMPROBE prototype was designed and built in our institution. Men on active surveillance due prostate resampling were invited to have a CAMPROBE biopsy as an alternative to repeat transrectal ultrasound-guided prostate biopsies (TRUSBx) as part of an approved trial (NCT02375035). Biopsies were performed using LA infiltration only, without sedation or additional analgesia. Patient-reported outcomes were recorded at day 0 and 7 using validated questionnaires and visual analogue scales (VAS). Complications were recorded prospectively.


Thirty men underwent biopsies with a median of 11 cores taken per procedure (interquartile range 10-12). There were no infections, sepsis or retention episodes. Haematuria and haematospermia occurred in 67% and 62% of patients, which are similar to rates reported for TRUSBx. Mean VAS for pain (0-10 scale) was less than 3 for every part of the procedure. All 30 men described the procedure as tolerable under LA. In total, 26/30 (86.7%) men expressed a preference for a CAMPROBE procedure over TRUSBx and a further 3 (10.0%) would have either.


In this small pilot study, the CAMPROBE device and method appears to be a safe, simple and well-tolerated out-patient transperineal replacement for TRUSBx. A major new National Institute for Health Research grant will allow its further development from a prototype to a single use, low-cost disposable device ready for multi-centre testing.

Level of evidence:

1b: individual cohort study.


Prostate cancer; diagnostic intervention; patient safety; service delivery; transperineal biopsy

Conflict of interest statement

Conflicting interests: The authors declare that there is no conflict of interest.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center